Becton Dickinson (BDX) announced it has received FDA 510(k) clearance and Conformite Europeenne marking in the European Union for its Enteric Bacterial Panel and Enteric Bacterial Panel plus for the BD COR System.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- BD’s New Vascular Access Study: What Investors Need to Know
- BDX’s SiteRite 9 Study: A New Frontier in Ultrasound-Guided Vascular Access
- Becton, Dickinson’s New Study on Sepsis Diagnostic Vials: Market Implications
- BDX’s Innovative Study on BD PosiFlush™ SafeScrub: Market Insights
- Ulta Beauty names Christopher DelOrefice CFO